Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

Ralf Gold, Giancarlo Comi, Jacqueline Palace, Arno Siever, Rebecca Gottschalk, Mahendra Bijarnia, Philipp von Rosenstiel, Davorka Tomic, Ludwig Kappos, FIRST Study Investigators, Ralf Gold, Giancarlo Comi, Jacqueline Palace, Arno Siever, Rebecca Gottschalk, Mahendra Bijarnia, Philipp von Rosenstiel, Davorka Tomic, Ludwig Kappos, FIRST Study Investigators

Abstract

The aim of this study was to evaluate short-term safety and tolerability of fingolimod in a real-world population with relapsing multiple sclerosis, focusing on cardiac safety during treatment initiation. Patients received fingolimod 0.5 mg once daily for four months. Patients excluded from the pivotal studies with certain pre-existing cardiac conditions or baseline cardiac findings (PCCs), and those receiving beta blockers (BBs) and/or calcium channel blockers (CCBs), were eligible. Heart rate (HR) and electrical conduction events were monitored using ambulatory electrocardiography for at least 6 h after the first dose. Of 2,417 enrolled patients, 2,282 (94.4 %) completed the study. Fingolimod initiation was associated with a transient, mostly asymptomatic decrease in HR. Bradycardia adverse events occurred in 0.6 % of patients and were more frequent in individuals receiving BBs/CCBs (3.3 %) than in other patient subgroups (0.5-1.4 %); most events were asymptomatic, and all patients recovered without pharmacological intervention. In the 6 h post-dose, the incidences of Mobitz type I second-degree atrioventricular block (AVB) and 2:1 AVB were higher in patients with PCCs (4.1 and 2.0 %, respectively) than in those without (0.9 and 0.3 %, respectively); at pre-dose screening, patients with PCCs had the same incidence of Mobitz type I second-degree AVB (4.1 %) and a slightly lower incidence of 2:1 AVB (0.7 %) than 6 h post-dose. All recorded conduction abnormalities were asymptomatic. This study adds to the evidence showing that cardiac effects during fingolimod initiation remain consistent with those known from previous, controlled studies, even if patients with PCCs are included.

Figures

Fig. 1
Fig. 1
Hourly mean change in pulse rate from pre-dose sitting pulse rate (a) and mean change in pulse rate across visits from pre-dose sitting pulse rate (b) for patients who had/did not have pre-existing cardiac conditions or baseline cardiac findings (PCCs), and hourly mean change in pulse rate from pre-dose sitting pulse rate (c) and mean change in pulse rate across visits from pre-dose sitting pulse rate (d) for patients who were receiving/not receiving beta blockers/calcium channel blockers (BBs/CCBs). bpm beats per minute, NBB/NCCB not receiving BBs/CCBs, NPCC no PCCs
Fig. 2
Fig. 2
Time to nadir hourly heart rate (HR) in patients who had/did not have pre-existing cardiac conditions or baseline cardiac findings (PCCs) (a) and who were receiving/not receiving concomitant beta blockers/calcium channel blockers (BBs/CCBs) (b), and time to maximal change in HR 6 h following first-dose administration from equivalent time of day at screening for patients who had/did not have PCCs (c) and who were receiving/not receiving BBs/CCBs (d) Percentages were calculated using the total number of patients in each subpopulation (PCCs, n = 295; NPCCs, n = 2,120; BBs/CCBs, n = 120; NBB/NCCB, n = 2,295). NBB/NCCB not receiving BBs/CCBs, NPCC no PCCs, SD standard deviation

References

    1. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277(24):21453–21457. doi: 10.1074/jbc.C200176200.
    1. European Medicines Agency (2011) Annex I. Summary of product characteristics. Gilenya (fingolimod). . Accessed 8 October 2012
    1. European Medicines Agency (2012) Revised summary of product characteristics. Gilenya (fingolimod). . Accessed 8 October 2012
    1. US Food and Drug Administration (2010) Gilenya prescribing information. . Accessed 8 October 2012
    1. US Food and Drug Administration (2012) Gilenya (fingolimod): revised US prescribing information. . Accessed 8 October 2012
    1. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan K, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, Malhotra M, von Rosenstiel P, Lublin FD. Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS): Results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II Study) Neurology. 2012;78((suppl 1)):P01.133.
    1. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–415. doi: 10.1056/NEJMoa0907839.
    1. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. doi: 10.1056/NEJMoa0909494.
    1. Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transpl. 2005;5(3):529–536. doi: 10.1111/j.1600-6143.2005.00754.x.
    1. Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124–1140. doi: 10.1056/NEJMoa052643.
    1. ICH harmonized tripartite guideline–guideline for good clinical practice: E6(R1). Geneva: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. . Accessed 8 October 2012
    1. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire F. . Accessed 8 October 2012
    1. Polman C. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol. 2005;58:840–846. doi: 10.1002/ana.20703.
    1. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS) Neurology. 1983;33:1444–1452. doi: 10.1212/WNL.33.11.1444.
    1. DiMarco J, O’Connor P, Cohen J, Reder A, Zhang-Auberson L, Tang D, Collins W, Kappos L. Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies. Mult Scler. 2012;18(Suppl 4):55–227.
    1. Kovarik JM, Lu M, Riviere GJ, Barbet I, Maton S, Goldwater DR, Schmouder RL. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. Eur J Clin Pharmacol. 2008;64(5):457–463. doi: 10.1007/s00228-007-0448-4.
    1. Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci. 2012;23:167–172. doi: 10.1016/j.jns.2012.09.009.
    1. US Food and Drug Administration (2012) Gilenya (fingolimod): Drug safety communication–revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). . Accessed 8 October 2012

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir